When response to NAC and prognosis were compared among breast cancer-intrinsic subtypes, patients with luminal tumors had a lower pathologic complete response rate but showed better outcomes compared with triple negative type and HER2 type [24]. This evidence concerns the gene ERBB2 and breast cancer.